Subject Disposition
Study CDISCPILOT01 — Intent-to-Treat Analysis Set
	Placebo	Xanomeline Low Dose	Xanomeline High Dose	Total	
	(N=86)	(N=96)	(N=72)	(N=254)	
Disposition, n (%)					
Subjects randomised	86 (100.0%)	96 (100.0%)	72 (100.0%)	254 (100.0%)	
Subjects treated	86 (100.0%)	96 (100.0%)	72 (100.0%)	254 (100.0%)	
Completed the study	58 (67.4%)	25 (26.0%)	27 (37.5%)	110 (43.3%)	
Discontinued the study	28 (32.6%)	71 (74.0%)	45 (62.5%)	144 (56.7%)	
Reason for discontinuation, n (%)					
Death	2 (2.3%)	1 (1.0%)	0 (0.0%)	3 (1.2%)	
Other / not specified	26 (30.2%)	70 (72.9%)	45 (62.5%)	141 (55.5%)	
Deaths, n (%)					
Died on study	2 (2.3%)	1 (1.0%)	0 (0.0%)	3 (1.2%)	
Percentages are based on the number of randomised subjects in each treatment group.
The ADSL shipped in pharmaverseadam carries no DCSREAS/DCDECOD, so the reason for discontinuation is derived: 'Death' where DTHFL = 'Y', otherwise 'Other / not specified'.
52 screen failures are excluded from every analysis dataset.	
Source: adsl (pharmaverseadam). Data cut-off: 2014-07-01. open.csr display t-disposition (post-text variant); generated from the committed ARD.